MedPath

Phentolamine

Generic Name
Phentolamine
Brand Names
Oraverse
Drug Type
Small Molecule
Chemical Formula
C17H19N3O
CAS Number
50-60-2
Unique Ingredient Identifier
Z468598HBV
Background

Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine. It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis. Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.

Indication

1.用于预防和治疗嗜铬细胞瘤所致的高血压发作,包括手术切除时出现的阵发性高血压,也可根据血压对本品的反应用于协助诊断嗜铬细胞瘤;

2.治疗左心衰竭;

3.治疗去甲肾上腺素、去氧肾上腺素、间羟胺等静脉给药外溢,用于防止皮肤坏死;

4.临床还用于治疗男性勃起功能障碍(ED)。最新研究表明,本品与罂粟碱、前列地尔三联用药,可降低引起平滑肌收缩的交感神经张力,使阴茎动脉平滑肌松弛,增加阴茎动脉血流,有利勃起。

Associated Conditions
Mydriasis, Necrosis caused by norepinephrine extravasation, Pheochromocytoma, Sloughing Skin, Soft Tissue Anesthesia (Numbness), Hypertensive episodes

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

Early Phase 1
Not yet recruiting
Conditions
Menopause
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-03-28
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
75
Registration Number
NCT06787066

Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery

Not Applicable
Not yet recruiting
Conditions
Preoperative
Phentolamine
Intraoperative
Esmolol
Hypotensive Anesthesia
Functional Endoscopic Sinus Surgery
Interventions
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
Ain Shams University
Target Recruit Count
60
Registration Number
NCT06620991
Locations
🇪🇬

Ain Shams University, Cairo, Egypt

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Phase 3
Active, not recruiting
Conditions
Presbyopia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2025-03-05
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
545
Registration Number
NCT06542497
Locations
🇺🇸

United States, San Antonio, Texas, United States

The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II

Not Applicable
Recruiting
Conditions
Diabetes Mellitus, Type 1
Inflammation
Interventions
Drug: hyperinsulinaemic hypoglycaemic clamp
First Posted Date
2024-05-21
Last Posted Date
2025-04-04
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT06422494
Locations
🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands, Nijmegen, Gelderland, Netherlands

Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

Not Applicable
Not yet recruiting
Conditions
Severe Pre-eclampsia
Interventions
First Posted Date
2024-04-26
Last Posted Date
2024-04-26
Lead Sponsor
Assiut University
Target Recruit Count
200
Registration Number
NCT06385600

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects with Post-refractive Surgery Visual Disturbances

Phase 3
Active, not recruiting
Conditions
Mesopic Vision
Night Vision Loss
Interventions
First Posted Date
2024-04-05
Last Posted Date
2025-03-05
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
200
Registration Number
NCT06349759
Locations
🇺🇸

United States Phoenix, Pheonix, Arizona, United States

🇺🇸

United States Scottsdale, Scottsdale, Arizona, United States

🇺🇸

United States, Tampa, Florida, United States

and more 19 locations

Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI

Phase 2
Recruiting
Conditions
CA-AKI - Contrast-Associated Acute Kidney Injury
Coronary Artery Disease
Acute Coronary Syndrome
Adrenergic Receptor Antagonist Adverse Reaction
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-03-18
Lead Sponsor
Helwan University
Target Recruit Count
60
Registration Number
NCT06286059
Locations
🇪🇬

Badr university hospital, Badr, Cairo, Egypt

New Perspective on Exploring the Post-apneic BP Surge in Patients With OSA

Early Phase 1
Recruiting
Conditions
Obstructive Sleep Apnea
Interventions
First Posted Date
2023-12-15
Last Posted Date
2023-12-15
Lead Sponsor
Xu J
Target Recruit Count
350
Registration Number
NCT06172998
Locations
🇨🇳

Jing Xu, Huai'an, Jiangsu, China

Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences

First Posted Date
2023-08-18
Last Posted Date
2024-10-09
Lead Sponsor
University of Alberta
Target Recruit Count
30
Registration Number
NCT05997732
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
Other: Placebo
Other: Low dose pilocarpine vehicle
First Posted Date
2022-12-12
Last Posted Date
2023-11-24
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
333
Registration Number
NCT05646719
Locations
🇺🇸

Houston, TX, Houston, Texas, United States

🇺🇸

San Antonio, TX, San Antonio, Texas, United States

🇺🇸

Phoenix, AZ, Phoenix, Arizona, United States

and more 23 locations
© Copyright 2025. All Rights Reserved by MedPath